The good news … is that innovation is addressing diseases with high-unmet need such as oncology, autoimmune diseases, and central nervous system (CNS) disorders. But, there is a complicating factor in the economic story: the patient population benefiting from launch brands is becoming smaller.

Shares of Israel-based NeuroDerm Limited soared more than 16 percent in premarket trading after the company announced it was being snapped up by Tokyo-based Mitsubishi Tanabe Corporation.

San Diego-based Arena Pharmaceuticals announced that it had created an independent, privately held drug discovery incubator called Beacon Discovery.

After the announcement by Biogen that it was spinning off its hemophilia business, analysts and investors are pondering, somewhat quizzically, just what it means.

Scientists in Brazil have uncovered a new brain disorder associated with Zika infections in adults: an autoimmune syndrome called acute disseminated encephalomyelitis, or ADEM, that attacks the brain and spinal cord.   Zika has already been linked with the autoimmune disorder Guillain-Barre syndrome, which attacks peripheral nerves outside the brain and spinal cord, causing temporary […]

  11 billion euro R&D programme through 2020, with 5 billion euro dedicated to pre-clinical R&D and 1.5 billion euro planned for cooperation with external partners New partnerships with the Icahn School of Medicine at Mount Sinai, Massachusetts General Hospital, the Scripps Research Institute and Weill Cornell Medicine to discover new treatments for inflammatory bowel […]

After months of speculation on who Pfizer Inc. (PFE) will attempt to buy are now officially over — sort of. It has been confirmed that Pfizer Inc. and Allergan Plc (AGN), according to the Wall Street Journal, are discussing a potential merger. The two companies have declined to comment.   Analysts have been speculating on […]

EVANSTON, Ill., Sept. 16, 2015 /PRNewswire/ — Aptinyx Inc., a biopharmaceutical company advancing modulators of the N-methyl-D-aspartate (NMDA) receptor for the treatment of challenging disorders of the brain and nervous system, has launched with the discovery platform and preclinical pipeline spun out of Naurex upon the close of its acquisition by Allergan in August 2015. “As […]

Israel-based drugmaker Teva Pharmaceutical (TEVA) is snapping up Allergan Plc’s generic drug business for $40.5 billion, the company announced this morning. Under terms of the agreement, Allergan will receive $33.75 billion in cash and shares of Teva valued today at $6.75 billion, representing an estimated under 10 percent ownership stake in Teva, the company said. […]